The FDA is looking for mathletes, of a sort. Regulatory Focus reports that the FDA is looking to create a mathematical model that will help regulators assess the sameness of generics and maybe even biosimilars.
RF says the Center for Drug Evaluation and Research will oversee the three-year project which will cost around $1 million.
